

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: **June 30, 2012**

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File No. **000-53298**

MYOS CORPORATION

(Exact name of registrant as specified in its charter)

Nevada

90-0772394

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

45 Horsehill Road, Suite 106 Cedar Knolls, NJ.

07927

(Address of Principal Executive Offices)

(Zip Code)

(973) 509-0444

(Registrant's telephone number, including area code)

ATLAS THERAPEUTICS CORPORATION

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes No

As of August 2, 2012, the registrant had 108,671,307 shares of common stock outstanding.

INDEX

Page

PART I-FINANCIAL INFORMATION

2

Item 1. Financial Statements

Consolidated Balance Sheets as of June 30, 2012 (unaudited) and December 31, 2011

2

Consolidated Statements of Operations (unaudited) for the three and six months ended June 30, 2012 and 2011 and the period from inception (April 11, 2007) to June 30, 2012

3

Consolidated Statement of Changes in Stockholders' Equity (unaudited) for the period from inception (April 11, 2007) to June 30, 2012

4

Consolidated Statements of Cash Flows (unaudited) for the six months ended June 30, 2012 and 2011 and the period from inception (April 11, 2007) to June 30, 2012

5 to 6

Notes to Consolidated Financial Statements

7 to 19

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

20 to 22

Item 3. Quantitative and Qualitative Disclosures about Market Risk

23

Item 4. Control and Procedures

23

PART II-OTHER INFORMATION

Item 1. Legal Proceedings

24

Item 1A. Risk Factors

24

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

24

Item 3. Defaults Upon Senior Securities

24

Item 4. Mine Safety Disclosures

24

Item 5. Other Information

24

Item 6. Exhibits

25

SIGNATURES

26

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

**MYOS CORPORATION AND SUBSIDIARY
(a development stage company)
CONSOLIDATED BALANCE SHEETS**

	June 30, 2012 (Unaudited)	December 31, 2011
ASSETS		
Current assets		
Cash	\$ 571,840	\$ 61,266
Accounts receivable	2,387	17,557
Inventories	436,580	526,284
Deferred financing cost	-	49,451
Prepaid expenses and other current assets	58,498	140,336
Total current assets	1,069,305	794,894
Fixed assets, net of accumulated depreciation of \$729	4,340	2,748
Intellectual property	2,000,000	2,000,000
Security deposits	-	10,000
Total assets	<u>\$ 3,073,645</u>	<u>\$ 2,807,642</u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities		
Accounts payable and accrued expenses	\$ 75,641	\$ 411,665
Note payable - stockholder	65,000	-
Note payable for acquisition of intellectual property	-	350,000
Convertible notes payable	-	400,000
Accrued interest	701	18,400
Accounts payable and accrued expenses - related parties	45,911	132,934
Loans payable	-	60,000
Notes payable - directors	-	80,000
Note payable	7,500	7,500
Total current liabilities	194,753	1,460,499
Derivatives liability	375,741	872,659
Total liabilities	570,494	2,333,158
Stockholders' equity		
Preferred stock, \$.001 par value; 25,000,000 shares authorized; no shares issued and outstanding	-	-
Common stock, \$.001 par value, 300,000,000 shares authorized; 87,566,307 shares issued and outstanding at June 30, 2012 66,813,997 shares issued and outstanding at December 31, 2011	87,566	66,814
Additional paid-in capital	10,230,539	6,138,916
Deficit accumulated during development stage	(7,814,954)	(5,731,246)
Total stockholders' equity	2,503,151	474,484
Total liabilities and stockholders' equity	<u>\$ 3,073,645</u>	<u>\$ 2,807,642</u>

The accompanying notes are an integral part of the consolidated financial statements

MYOS CORPORATION AND SUBSIDIARY
(a development stage company)
CONSOLIDATED STATEMENTS OF OPERATIONS

	Three Months Ended June 30,		Six Months Ended June 30,		April 11, 2007 (Inception Date) to June 30, 2012
	2012	2011	2012	2011	2012
Revenue	\$ 343,889	\$ -	\$ 368,429	\$ -	\$ 467,904
Cost of sales	<u>292,851</u>	<u>-</u>	<u>301,407</u>	<u>-</u>	<u>351,339</u>
Gross profit	51,038	-	67,022	-	116,565
General and administrative expenses	<u>593,998</u>	<u>613,121</u>	<u>1,033,007</u>	<u>2,324,387</u>	<u>5,824,986</u>
Loss from operations	<u>(542,960)</u>	<u>(613,121)</u>	<u>(965,985)</u>	<u>(2,324,387)</u>	<u>(5,708,421)</u>
OTHER INCOME (EXPENSE)					
Interest expense	(778,761)	(5,677)	(802,508)	(7,936)	(827,709)
Value of warrants in excess of the amount of additional paid-in capital received in the related private placement of restricted common stock				(2,373,248)	(2,405,303)
Change in fair value of warrants	(227,685)	(1,448,481)	(245,764)	(942,335)	3,855,979
Impairment charge - intellectual property					(2,662,000)
Amortization of deferred financing costs	(35,451)	(482,335)	(69,451)		(80,000)
Gain on forgiveness of debt					12,500
	<u>(1,041,897)</u>	<u>(1,936,493)</u>	<u>(1,117,723)</u>	<u>(3,323,519)</u>	<u>(2,106,533)</u>
Net loss	<u>\$ (1,584,857)</u>	<u>\$ (2,549,614)</u>	<u>\$ (2,083,708)</u>	<u>\$ (5,647,906)</u>	<u>\$ (7,814,954)</u>
Weighted average number of common shares outstanding, basic and diluted	79,944,399	61,317,314	75,720,132	57,407,505	
Basic and diluted net loss per share attributable to common stockholders	\$ (0.02)	\$ (0.04)	\$ (0.03)	\$ (0.10)	

The accompanying notes are an integral part of the consolidated financial statements

MYOS CORPORATION AND SUBSIDIARY
(a development stage company)
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY
For the period from April 11, 2007 (date of inception) to June 30, 2012

	Common Stock		Additional paid-in capital	Deficit accumulated during development stage	Total stockholders' equity (deficit)
	Shares	Amount \$.001 par			
Balance at April 11, 2007	-	\$ -	\$ -	\$ -	\$ -
Common stock issued for cash at \$0.0002 per share	28,000,000	28,000	(23,000)		5,000
Common stock issued for cash at \$0.004 per share	21,000,000	21,000	54,000		75,000
Net loss				(60,185)	(60,185)
Balance at December 31, 2007	49,000,000	49,000	31,000	(60,185)	19,815
Net loss				(17,928)	(17,928)
Balance at December 31, 2008	49,000,000	49,000	31,000	(78,113)	1,887
Net loss				(39,308)	(39,308)
Balance at December 31, 2009	49,000,000	49,000	31,000	(117,421)	(37,421)
Net loss				(16,525)	(16,525)
Balance at December 31, 2010	49,000,000	49,000	31,000	(133,946)	(53,946)
Issuance of 7,024,000 shares of Common Stock to Peak Wellness, Inc. as part of the purchase price of intellectual property	7,024,000	7,024	3,504,976		3,512,000
Fair value of shares transferred from existing stockholder to the CEO in connection with employment agreement			1,500,000		1,500,000
Proceeds from private placements of restricted common stock	8,334,997	8,335	2,472,165		2,480,500
Offering costs			(45,000)		(45,000)
Fair value of warrants issued to private placement investors			(2,432,365)		(2,432,365)
Shares issued for services	2,055,000	2,055	688,138		690,193
Vesting of options and shares issued to directors and advisory board members			360,402		360,402
Shares issued in connection with debt	400,000	400	59,600		60,000
Net loss				(5,597,300)	(5,597,300)
Balance at December 31, 2011	66,813,997	66,814	6,138,916	(5,731,246)	474,484
Proceeds from private placements of restricted common stock	13,850,000	13,850	1,731,150		1,745,000
Shares issued to COO, not vested	750,000	750	(750)		-
Shares issued for services	1,930,000	1,930	143,095		145,025
Shares issued in debt conversions	2,716,306	2,716	1,301,111		1,303,827
Shares issued in exchange for warrants	1,506,004	1,506	721,376		722,882
Vesting of options and shares issued to officers, directors and advisory board members			195,641		195,641
Net loss				(2,083,708)	(2,083,708)
Balance at June 30, 2012	<u>87,566,307</u>	<u>\$ 87,566</u>	<u>\$ 10,230,539</u>	<u>\$ (7,814,954)</u>	<u>\$ 2,503,151</u>

The accompanying notes are an integral part of the consolidated financial statements

MYOS CORPORATION AND SUBSIDIARY
(a development stage company)
CONSOLIDATED STATEMENTS OF CASH FLOW

	Six Months Ended June 30,		April 11, 2007 (Inception Date) to June 30,
	2012	2011	2012
Cash Flows from Operating Activities			
Net loss	\$ (2,083,708)	\$ (5,647,906)	\$ (7,814,954)
Adjustments to reconcile net loss to net cash used in operating activities:			
Depreciation	452	105	728
Stock based compensation	380,666	1,600,933	2,931,261
Loss on debt conversion	883,827		883,827
Impairment charges			2,662,000
Derivatives charges and credits	225,964	3,315,583	(1,333,742)
Changes in operating assets and liabilities			
(Increase) decrease in accounts receivable	15,170		(2,387)
(Increase) decrease in inventories	89,704	(335,830)	(436,580)
Decrease in deferred financing cost	49,451		49,451
(Increase) decrease in prepaid expenses and other assets	81,838	(373,463)	(15,449)
Increase (decrease) in accounts payable and accrued expenses	(353,723)	33,478	76,342
Net cash used in operating activities	<u>(710,359)</u>	<u>(1,407,100)</u>	<u>(2,999,503)</u>
Cash Flows from Investing Activities			
Acquisition of intellectual property		(450,000)	(450,000)
Acquisition of fixed assets	(2,044)	(1,569)	(5,068)
Decrease in security deposits	10,000		10,000
Net cash used in investing activities	<u>7,956</u>	<u>(451,569)</u>	<u>(445,068)</u>
Cash Flows from Financing Activities			
(Repayments to) advances from related parties	(227,023)		(86,589)
Note payable - stockholder	65,000		65,000
Repayment of notes payable	(350,000)		(742,500)
Insurance financing note		(24,903)	
Offering costs			(45,000)
Proceeds from issuance of stock to initial stockholders			80,000
Proceeds from issuance of notes			540,000
Proceeds from private placement of common stock	1,725,000	2,412,756	4,205,500
Net cash provided by financing activities	<u>1,212,977</u>	<u>2,387,853</u>	<u>4,016,411</u>
Net increase in cash	510,574	529,184	571,840
Cash at beginning of the period	61,266	-	-
Cash at end of the period	<u>\$ 571,840</u>	<u>\$ 529,184</u>	<u>\$ 571,840</u>

The accompanying notes are an integral part of the consolidated financial statements

MYOS CORPORATION AND SUBSIDIARY
(a development stage company)
CONSOLIDATED STATEMENTS OF CASH FLOW (Continued)

	Six Months Ended June 30, 2012	Six Months Ended June 30, 2011	April 11, 2007 (Inception Date) to June 30, 2012
Supplemental Disclosure of Cash Flow Information:			
Cash paid for franchise taxes	\$ 1,550	\$ 800	\$ 2,350
Cash paid for interest	\$ -	\$ -	\$ -
Supplemental Disclosure of Non-Cash Transactions:			
Offering costs paid by stockholder	\$ -	\$ 25,000	\$ 25,000
Conversion of stockholder loan and interest into common stock	\$ 443,761	\$ 2,744	\$ 446,505
Conversion of stockholder loan into capital - no shares issued	\$ -	\$ 22,256	\$ 22,256
Conversion of 7,529,999 warrants into 1,506,004 common shares	\$ 722,882	\$ -	\$ 722,882
Note payable - insurance financing	\$ -	\$ 42,500	\$ 42,500
Note issued for accounts payable	\$ -	\$ -	\$ 7,500
Acquisition of intellectual property through note payable	\$ -	\$ 700,000	\$ 700,000
Issuance of 200,000 shares of common stock pursuant to price protection provision in subscription agreement	\$ 20,000	\$ -	\$ 80,000

The accompanying notes are an integral part of the consolidated financial statements

MYOS CORPORATION AND SUBSIDIARY
(a development stage company)
Notes to Consolidated Financial Statements
June 30, 2012 and 2011

NOTE 1 – NATURE OF ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

Organization & Business Activities

MYOS Corporation, formerly known as Atlas Therapeutics Corporation (the "Company"), was incorporated under the laws of the State of Nevada on April 11, 2007. On February 25, 2011, the Company entered into an agreement to purchase certain intellectual property from Peak Wellness, Inc. (the "Acquisition"). Since the Acquisition, the Company's business focus has been on the discovery, development and commercialization of therapeutic products, nutritional supplements and other technologies aimed at improving the health and performance of muscle tissue (see Note 8 – Intellectual Property Purchase Agreement). The Company has only realized revenues of \$467,904 through June 30, 2012 without fully implementing its plan of operations and therefore is still considered a development stage company.

Depreciation

The cost of property and equipment will be depreciated over the estimated useful life of 4 to 7 years. Depreciation is computed using the straight-line method when assets are placed in service.

Basis of Accounting and Principles of Consolidation

The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in accordance with generally accepted accounting principles and include the accounts of the Company and its wholly-owned subsidiary, Atlas Acquisition Corp. (formed on February 23, 2011 to facilitate the purchase of the intellectual property discussed in Note 8). All material intercompany balances and transactions have been eliminated.

Cash Equivalents

The Company considers all highly liquid investments purchased with a maturity of three months or less to be a cash equivalent.

Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues & expenses during the reporting period.

Fair Value of Indefinite-Lived Intangible Assets

The Company's policy is to evaluate indefinite-lived intangible assets for possible impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An intangible asset with an indefinite life (the intellectual property) is evaluated for possible impairment by comparing the fair value of the asset with its carrying value. Fair value is estimated as the discounted value of future revenues arising from a trademark using a royalty rate that an independent party would pay for use of that trademark. An impairment charge is recorded if the trademark's carrying value exceeds its estimated fair value. An impairment charge is recorded if the carrying value of the goodwill exceeds its implied fair value. See Note 8 for information related to impairment charges recorded in 2011 for indefinite-lived intellectual property intangible assets.

MYOS CORPORATION AND SUBSIDIARY
(a development stage company)
Notes to Consolidated Financial Statements
June 30, 2012 and 2011

Revenue Recognition

The Company recognizes revenue when products are shipped and collection is reasonably assured.

Inventories

Inventories are stated at the lower of cost or market, with cost generally determined on a first-in, first-out basis.

Advertising

The Company charges the costs of advertising to expense as incurred. The Company incurred \$1,000 of advertising and promotional costs for the period ended June 30, 2012 and \$359,489 since its inception.

Fixed Assets

Fixed assets consists solely of office equipment and are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of 5 to 7 years. Repair and maintenance costs are expensed as incurred. Depreciation expense for the period ended June 30, 2012 was \$452.

Concentrations of Risk

The Company's bank accounts are deposited in insured institutions. From December 31, 2010 through December 31, 2012, all non-interest-bearing transaction accounts will be fully insured by the FDIC, regardless of the balance of the account and the ownership capacity of the funds. Since all of the Company's cash in banks at June 30, 2012 were deposited in a checking account which is considered a noninterest-bearing transaction account, all of its funds are currently insured regardless of the balance. Subsequent to June 30, 2012, as a result of the proceeds from private placement described in Note 11, we had substantially higher balances in interest bearing accounts and, accordingly, are now subject to the risk of uninsured bank balances.

Equity Based Compensation

The Company accounts for equity-based compensation under the provisions of ASC 718-10 Compensation - Stock Compensation and ASC 505-50 Equity Based Payments to Non-Employees. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. For stock options and restricted stock that do not vest immediately but which contain only a service vesting feature, we recognize compensation cost on the unvested shares and options on a straight-line basis over the remaining vesting period, net of any projected forfeitures

The Company uses the Black-Scholes option-pricing model as its method of valuation for share-based compensation. Our determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to our expected stock price volatility over the term of the awards, and certain other market variables such as the risk free interest rate. Equity-based compensation expense for awards to employees and non-employees recognized was \$380,666 and \$1,600,933 for the periods ended June 30, 2012 and 2011, respectively.

Comprehensive Loss

The Company had no items of other comprehensive income or expense for the years ended June 30, 2012 and 2011, respectively. Accordingly, the Company's comprehensive loss and net loss are the same for all periods presented.

Segment Information

ASC 280, "Disclosures about Segments of an Enterprise and Related Information", establishes standards for reporting information regarding operating segments in annual consolidated financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders. It also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The Company operates in a single segment, internally reports the results of operations for that segment and the information disclosed herein materially represents all of the financial information related to the single operating segment.

MYOS CORPORATION AND SUBSIDIARY
(a development stage company)
Notes to Consolidated Financial Statements
June 30, 2012 and 2011

Fair Value Measurement

The Company adopted the provisions of ASC 820 “Fair Value Measurements and Disclosures” on January 1, 2009, the beginning of our 2009 fiscal year. ASC 820 clarifies the principle that fair value should be based on the assumptions market participants would use when pricing an asset or liability and establishes a fair value hierarchy that prioritizes the information used to develop those assumptions. Under the standard, fair value measurements are separately disclosed by level within the fair value hierarchy. As originally issued, it was effective for fiscal years beginning after November 15, 2007, with early adoption permitted. It does not require any new fair value measurements. It only applies to accounting pronouncements that already require or permit fair value measures, except for standards that relate to share-based payments.

On February 12, 2008, the FASB allowed deferral of the effective date of ASC 820 for one year, as it relates to nonfinancial assets and liabilities. Accordingly, our adoption related only to financial assets and liabilities. Upon adoption ASC 820, there was no cumulative effect adjustment to beginning retained earnings and no impact on the consolidated financial statements as of December 31, 2010 and 2009, respectively.

Valuation techniques considered under ASC 820 techniques are based on observable and unobservable inputs. The ASC classifies these inputs into the following hierarchy:

Level 1 inputs are observable inputs and use quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date and are deemed to be most reliable measure of fair value.

Level 2 inputs are observable inputs and reflect assumptions that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the reporting entity. Level 2 inputs includes 1) quoted prices for similar assets or liabilities in active markets, 2) quoted prices for identical or similar assets or liabilities in markets that are not active, 3) observable inputs such as interest rates and yield curves observable at commonly quoted intervals, volatilities, prepayment speeds, credits risks, default rates, and 4) market-corroborated inputs.

Level 3 inputs are unobservable inputs and reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing the asset or liability based on the best information available under the circumstances.

In October 2008, the FASB clarified the application of ASC 820 in determining the fair value of a financial asset when the market for that financial asset is not active.

The Company adopted the provisions of ASC 825, “The Fair Value Option for Financial Assets and Liabilities”, on January 1, 2009, the beginning of our 2009 fiscal year. ASC 825 permits us to choose to measure certain financial assets and liabilities at fair value that are not currently required to be measured at fair value (the “Fair Value Option”). Election of the Fair Value Option is made on an instrument-by-instrument basis and is irrevocable. At the adoption date, unrealized gains and losses on financial assets and liabilities for which the Fair Value Option has been elected are reported as a cumulative adjustment to beginning retained earnings.

Our intangible assets are valued and tested for impairment using Level 3 inputs (see Note 8). In the process of the valuation of the intangible asset, we determined that the carrying cost exceeded the fair value at December 31, 2011 and we recorded an impairment charge and adjusted the balance of the asset to reflect the fair value.

Basic and Diluted Income (Loss) per Share

In accordance with ASC 260, Earnings Per Share, the basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding. Diluted loss per common share is computed in a manner similar to basic loss per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. At June 30, 2012 and 2011, the Company’s stock equivalents were anti-dilutive and excluded in the diluted loss per share computation. The aggregate number of potentially dilutive warrants and options outstanding at June 30, 2012 were 2,254,998.

MYOS CORPORATION AND SUBSIDIARY
(a development stage company)
Notes to Consolidated Financial Statements
June 30, 2012 and 2011

Income Taxes

Income taxes are accounted for under the asset and liability method in accordance with ASC 740, Income Taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the periods in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance to the extent that the recoverability of the asset is unlikely to be recognized.

The Company follows ASC 740 rules governing uncertain tax positions, which provides guidance for recognition and measurement. This prescribes a threshold condition that a tax position must meet for any of the benefits of the uncertain tax position to be recognized in the financial statements. It also provides accounting guidance on recognition, classification and disclosure of these uncertain tax positions. The Company has no uncertain income tax positions.

Interest costs and penalties related to income taxes are classified as interest expense and selling, general and administrative costs, respectively, in the Company's financial statements. For the six months ended June 30, 2012 and 2011, the Company did not recognize any interest or penalty expense related to income taxes. The Company files income tax returns in the U.S. federal jurisdiction and states in which it does business.

NOTE 2- PRIVATE PLACEMENTS OF RESTRICTED COMMON STOCK

During April 2007, the Company sold 28,000,000 (after adjusting for the 1 to 14 split) shares of its common stock to its founders for cash proceeds of \$5,000. During December 2007, the company sold 21,000,000 (after adjusting for the 1 to 14 split) shares of its common stock in a private placement for cash of proceeds \$75,000.

From February 25 through July 12, 2011, the Company issued an aggregate of 8,134,997 shares of common stock and warrants to purchase 8,134,997 shares of common stock to certain investors (the "Private Placements"). Each warrant has a three-year term and is exercisable at \$0.60 per share (currently at \$.10 due to the triggering of a down round full ratchet anti dilution provision). The warrants are redeemable by the Company in the event the Company's common stock exceeds \$3.00 for twenty of thirty trading days. The Company granted piggy-back registration rights for the securities issued in the Private Placements.

On December 2, 2011, one investor purchased 200,000 shares for gross proceeds of \$40,000 in a private placement. The subscription agreement contains a "Purchase Price Protection" clause that grants the investor additional shares in the event of a private placement during the 10 month period from the date of the investment at a price per share less than the investor's purchase price. The additional shares shall be issued for no additional payment such that the total per share price paid by this investor will equal the amount paid by investors in such later private placement. In April 2012, the Company issued an additional 200,000 shares to the investor as a result of the price protection provision.

During February and March 2012, the Company issued an aggregate of 10,250,000 shares of restricted common stock to certain accredited investors in a private placement and received aggregate gross proceeds of \$1,025,000. The securities are subject to piggyback registration rights.

In April 2012, the Company issued an aggregate of 1,000,000 shares of restricted common stock to one accredited investor in a private placement and received aggregate gross proceeds of \$100,000. The securities are subject to piggyback registration rights.

In June 2012, the Company issued an aggregate of 2,400,000 shares of restricted common stock to certain accredited investors in a private placement and received aggregate gross proceeds of \$600,000. The securities are subject to piggyback registration rights.

See subsequent events for private placements of restricted common stock in July 2012.

MYOS CORPORATION AND SUBSIDIARY
(a development stage company)
Notes to Consolidated Financial Statements
June 30, 2012 and 2011

The Company received aggregate gross proceeds of \$4,205,500 from the private placements as follows:

Date	Shares	Gross Proceeds	Related Warrant Liability at Inception	Related Warrant Liability at June 30, 2012
February 25, 2011	4,766,666	\$ 1,430,000	\$ 2,350,251	\$ 49,583
May 31, 2011	1,409,999	423,000	1,186,859	191,307
June 27, 2011	1,874,999	562,500	1,243,838	18,001
July 12, 2011	83,333	25,000	57,742	-
December 2, 2011	200,000	40,000	-	-
February 10, 2012	3,250,000	325,000	-	-
February 14, 2012	4,000,000	400,000	-	-
March 7, 2012	1,000,000	100,000	-	-
March 15, 2012	1,750,000	175,000	-	-
March 22, 2012	250,000	25,000	-	-
April 9, 2012	1,000,000	100,000	-	-
April 24, 2012	* 200,000	-	-	-
June 28, 2012	2,400,000	600,000	-	-
	<u>22,184,997</u>	<u>\$ 4,205,500</u>	<u>\$ 4,838,690</u>	<u>\$ 258,891</u>

* Shares issued under price protection provision of subscription agreement as described above.

The warrants are subject to full ratchet anti-dilution protection if the Company sells shares or share-indexed financing instruments at less than the \$0.60 exercise price. Repricing events occurred twice since the warrants were issued, once to \$0.20 on December 2, 2011 and again to \$0.10 on February 10, 2012 as a result of private placements of restricted common stock. The warrants issued in this financing arrangement did not meet the conditions for equity classification and are required to be carried as a derivative liability, at fair value. Management estimates the fair value of the warrants on the inception dates, and subsequently at each reporting period, using the Black-Scholes option-pricing model, adjusted for dilution, because that technique embodies all of the assumptions (including volatility, expected terms, dilution and risk free rates) that are necessary to determine the fair value of freestanding warrants.

On June 27, 2012, holders owning an aggregate of 7,529,999 warrants exchanged those warrants for 1,506,004 shares of common stock.

NOTE 3 - RECENT ACCOUNTING PRONOUNCEMENTS

The Company does not believe that the adoption of any recently issued, but not yet effective, accounting standards will have a material effect on its financial position and results of operations.

NOTE 4 - ADVANCES, ACCOUNTS PAYABLE AND ACCRUED EXPENSES - RELATED PARTIES

A former officer/director advanced an aggregate \$45,911 to the Company in 2010 and 2009, which was the balance due at December 31, 2011. The aggregate balance due to all related parties for advances, accounts payable and accrued expenses at June 30, 2012 was \$45,911. The advances and other amounts due are all non-interest bearing and due and payable upon demand.

MYOS CORPORATION AND SUBSIDIARY
(a development stage company)
Notes to Consolidated Financial Statements
June 30, 2012 and 2011

NOTE 5 - NOTES AND LOANS PAYABLE

Convertible Notes Payable

On November 29, 2011, the Company received aggregate proceeds of \$400,000 from two individuals (\$150,000 of which was from a director of the Company) on notes payable bearing interest at 18%, due on May 29, 2012 and convertible into common stock at the rate of \$0.20 per share or an adjusted lower rate determined by reference to a subsequent qualified financing. As additional consideration, the note holders were issued an aggregate of 400,000 shares of common stock valued at \$0.15 per share for an aggregate of \$60,000. The value of the shares issued were recorded as deferred financing costs and were amortized over the 6 month term of the notes. The unamortized balances were \$NIL at June 30, 2012 and \$49,451 at December 31, 2011. Related amortization expense was \$49,451 for the six months ended June 30, 2012.

On June 28, 2012, the aggregate principal of \$400,000 and the accrued interest of \$41,800 on the note was converted into 2,209,000 shares of restricted common stock at \$0.20 per share, the value of which exceeded the principal and interest by \$760,566 on the conversion date. This amount was charged to operations as an expense in the period ended June 30, 2012.

Notes Payable to Director

A director loaned the Company \$99,500, of which \$60,000 was advanced on September 29, 2011 and is evidenced by an unsecured note payable which was due on October 29, 2011 bearing interest at 3%; \$10,000 was advanced in October 2011; \$10,000 was advanced in December 2011 for direct payment to a vendor and \$19,500 of which was advanced in January 2012 for direct payments to vendors. On June 28, 2012, the principal plus accrued interest on the loans and advances of \$1,961 (aggregate of \$101,461) were converted into 507,306 shares of common stock at \$0.20 per share.

Note Payable

On May 20, 2010, the Company issued a note for \$7,500 bearing interest at 5% in exchange for Maremanno Corporation's payment of \$7,500 on an open account payable balance. The note is due and payable upon demand. The principal balance of the note remained \$7,500 at both June 30, 2012 and December 31, 2011. Accrued interest payable on this note was \$701 and \$982 as of June 30, 2012 and December 31, 2011, respectively.

Loan Payable

In November and December 2011, an unrelated third party loaned the Company an aggregate of \$60,000, payable on demand without interest. The loan was repaid in February 2012.

Note Payable to Stockholder

On June 15, 2012, a stockholder loaned the Company \$65,000, payable on July 15, 2012 without interest. The loan was repaid in July 2012.

See Note 8 for a description of the terms of the note payable to Peak Wellness, Inc. for the acquisition of intellectual property.

NOTE 6 - CAPITAL STOCK

On February 12, 2010, the Company's articles of incorporation were amended to increase the number of authorized preferred shares to 25,000,000 and the number of authorized common shares to 300,000,000. The Company's 3,500,000 common shares outstanding were also forward split on a 14 shares for 1 basis with the result that 49,000,000 shares were issued and outstanding on that date. The accompanying financial statements reflect the forward stock split on a retroactive basis.

NOTE 7 - WARRANTS AND OPTIONS

During the year ended December 31, 2011, the Company issued a total of 8,284,999 warrants to purchase restricted common stock. Of those warrants, 8,134,999 were issued to private placement investors which are subject to down round full ratchet anti dilution provisions requiring periodic repricing if shares are later offered at lower prices. In May 2012 holders of 7,529,999 warrants received 1,506,004 shares of restricted common stock in exchange for those warrants.

MYOS CORPORATION AND SUBSIDIARY
(a development stage company)
Notes to Consolidated Financial Statements
June 30, 2012 and 2011

The following tables summarize warrants issued during the year ended December 31, 2011 to private placement stockholders and consultants. For the six months ended June 30, 2012, no warrants were issued and no expense was recognized.

Grant Date	Number of Warrants Issued	Number of Warrants Exchanged	Number of Warrants Outstanding	Exercise Price Original/Repriced	Expiration Term in Years
February 25, 2011 (A)	4,766,666	4,650,000	116,666	\$ 0.60 /\$0.10	2.67
May 31, 2011 (A)	1,409,999	963,333	446,666	\$ 0.60/\$0.10	2.92
June 27, 2011 (A)	1,875,001	1,833,333	41,668	\$ 0.60/\$0.10	3.00
June 27, 2011 (B)	100,000	-	100,000	\$ 1.00	2.00
July 12, 2011 (A)	83,333	83,333	-	\$ 0.60/\$0.10	3.00
December 27, 2011 (B)	50,000	-	50,000	\$ 1.00	2.00

(A) Private placement warrants (these warrants are subject to down round full ratchet anti dilution provisions and based on the 2012 private placements at \$0.10 per share, the exercise price has been adjusted to \$0.10 until such later time as a lower down round offering takes place)

(B) Sponsorship agreement, including put option - see Note 10

Activity in warrants for each of the year ended December 31, 2011 and the six months ended June 30, 2012 is summarized as follows:

	Shares Under Warrants	Weighted Average Exercise Price Original/Repriced
Balance at January 1, 2011	-	
Warrants granted	8,284,997	\$ 0.61/\$0.10
Warrants exercised	-	
Warrants cancelled/expired	-	
Balance at December 31, 2011	8,284,997	\$ 0.61/\$0.10
Warrants granted	-	
Warrants exercised	-	
Warrants cancelled/exchanged/expired	(7,529,999)	
Balance at June 30, 2012	754,998	\$ 0.61/\$0.10

The following table summarizes information about warrants outstanding and exercisable at June 30, 2012. As all warrants currently outstanding are fully and immediately vested at issuance, the information for both outstanding and exercisable are identical.

Warrants Outstanding and Exercisable

Range of Exercise Price	Warrants Outstanding and Exercisable	Weighted Average Remaining Contractual Life
\$ 0.60(A)	604,998	2.30
\$ 1.00	150,000	1.66

(A) The exercise price decreased to \$0.10 in 2012 upon the closing of certain private placements

MYOS CORPORATION AND SUBSIDIARY
(a development stage company)
Notes to Consolidated Financial Statements
June 30, 2012 and 2011

The following table summarizes the assumptions used to value the warrants using the Black-Scholes option pricing model:

Grant Date	Number of Warrants Issued/ Outstanding	Stock Price on Measurement Date	Exercise Price	Expected Term	Expected Volatility	Dividend Yield	Risk Free Rate
(A)02/25/11	4,766,666	\$ 0.500	\$ 0.60	3.00	285.20%	0.00%	1.48%
(B)Remeasurement	116,666	\$ 0.480	\$ 0.10	1.92	184.00%	0.00%	0.51%
(A)05/31/11	1,409,999	\$ 0.850	\$ 0.60	3.00	208.89%	0.00%	0.79%
(B)Remeasurement	446,666	\$ 0.480	\$ 0.10	2.17	184.00%	0.00%	0.51%
(A)06/27/11	1,874,999	\$ 0.670	\$ 0.60	3.00	295.31%	0.00%	0.64%
(B)Remeasurement	41,668	\$ 0.480	\$ 0.10	2.25	184.00%	0.00%	0.51%
(A)07/12/11	83,333	\$ 0.700	\$ 0.60	3.00	278.00%	0.00%	0.42%
(B)Remeasurement	-	\$ 0.480	\$ 0.10	2.33	184.00%	0.00%	0.51%
(C)06/27/11	100,000	\$ 0.670	\$ 1.00	2.00	213.59%	0.00%	0.41%
(C)12/23/11	50,000	\$ 0.090	\$ 1.00	2.00	209.00%	0.00%	0.28%

(A) Private placement warrants

(B) Remeasurement required at end of each period because of the down round full ratchet anti dilution provision

(C) Sponsorship agreement, including put option - see Note 10

In July and August 2011, the Company issued an aggregate of 1,250,000 options to purchase restricted common stock to the following directors and scientific advisory board members (see Note 10).

Issued to and Grant Date	Number of Options	Exercise Price	Expiration Term in Years
Dr. Louis Aronne - director - July 14, 2011	250,000	\$ 0.64	10
Dr. Louis Aronne - scientific advisory board - July 14, 2011	500,000	\$ 0.64	10
Dr. Robert Hariri - director - July 26, 2011	250,000	\$ 0.69	10
Dr. Peter Diamandis - director - August 15, 2011	250,000	\$ 0.45	10
Dr. Buzz Aldrin - director - May 24, 2012	250,000	\$ 0.14	10

The following table summarizes the assumptions used to value the director/advisory board options using the Black-Scholes option pricing model:

Grant Date	Number of Options	Stock Price on Measurement Date	Exercise Price	Expected Term	Expected Volatility	Dividend Yield	Risk Free Rate
07/14/11	750,000	\$ 0.640	\$ 0.64	10.00	287.00%	0.00%	2.98%
07/26/11	250,000	\$ 0.690	\$ 0.69	10.00	285.00%	0.00%	2.99%
08/15/11	250,000	\$ 0.450	\$ 0.45	10.00	284.00%	0.00%	2.29%
05/24/12	250,000	\$ 0.140	\$ 0.45	10.00	187.00%	0.00%	1.77%

MYOS CORPORATION AND SUBSIDIARY
(a development stage company)
Notes to Consolidated Financial Statements
June 30, 2012 and 2011

Activity in stock options for each of the year ended December 31, 2011 and quarter ended June 30, 2012 is summarized as follows:

	Shares Under Options	Weighted Average Exercise Price
Balance at January 1, 2011	-	
Options granted	1,250,000	\$ 0.61
Options exercised	-	
Options cancelled/expired	-	
Balance at December 31, 2011	1,250,000	\$ 0.61
Options granted	250,000	0.14
Options exercised	-	
Options cancelled/expired	-	
Balance at June 30, 2012	<u>1,500,000</u>	\$ 0.53

At June 30, 2012, the weighted-average remaining term of the options was 9.07 years and the aggregate intrinsic value was \$81,250. The aggregate unvested cost of the options at June 30, 2012 was \$420,850.

The following table summarizes information about options outstanding and exercisable at June 30, 2012.

Options Outstanding			Options Exercisable		
Range of Exercise Price	Options Outstanding	Weighted Average Remaining Contractual Life	Range of Exercise Price	Options Exercisable	Weighted Average Remaining Contractual Life
\$ 0.64	750,000	9.04	\$ 0.64	208,333	9.04
\$ 0.69	250,000	9.08	\$ 0.69	83,333	9.08
\$ 0.45	250,000	9.13	\$ 0.45	83,333	9.13
\$ 0.14	250,000	9.92	\$ 0.14	83,333	9.90

NOTE 8 – INTELLECTUAL PROPERTY PURCHASE AGREEMENT

On February 25, 2011, the Company, Atlas Acquisition Corp., a wholly-owned subsidiary of the Company formed in February 2011 (“Atlas Sub”), and Peak Wellness, Inc. (“Peak”), entered into and consummated an Intellectual Property Purchase Agreement (the “Purchase Agreement”), pursuant to which Atlas Sub purchased certain intellectual property assets from Peak (the “Acquisition”). Pursuant to the Purchase Agreement, the Company acquired from Peak all intellectual property pertaining to MYO-T12, a natural-myostatin inhibitor, including the formula and process for making MYO-T12, certain trademarks, trade secrets, patent applications and certain domain names. The aggregate consideration for MYO-T12 was \$4,662,000 paid in cash, a promissory note and shares of common stock. The contractually stated purchase price for the assets was \$1,150,000, of which \$450,000 was paid in cash and \$700,000 via the issuance of the promissory note. Additionally, the Company issued 7,024,000 shares of common stock with an aggregate fair value of \$3,512,000 to Peak as part of the purchase price of MYO-T12, representing 12% of the fully diluted voting common stock of the Company on the date of the Acquisition.

In connection with the Purchase Agreement, the Company issued a secured promissory note to Peak (the “Promissory Note”) in the amount of \$700,000 with interest accruing at an interest rate of 3% per annum. The Promissory Note was payable in two installments as follows: \$350,000 plus accrued interest was due within 180 days after the closing date of the Agreement (originally August 25, 2011 but extended to the earlier of November 30, 2011 or the closing of a certain financing and paid on November 29, 2011) and \$350,000 plus accrued interest was due on the first anniversary of the closing date of the Agreement and paid on February 21, 2012.

MYOS CORPORATION AND SUBSIDIARY
(a development stage company)
Notes to Consolidated Financial Statements
June 30, 2012 and 2011

In connection with the Purchase Agreement and the Promissory Note, the Company entered into a security agreement with Peak to secure the payments due under the Promissory Note (the "Security Agreement"). Pursuant to the Security Agreement, the Company granted Peak a continuing security interest in the assets purchased from Peak. The Security Agreement also secured all of the Company's obligations to Peak, whether related or unrelated to the Promissory Note. The security interest was released in February 2012 upon payment of the final installment of the Promissory Note. On the closing date of the Acquisition, new officers and a new director were appointed to serve the Company.

The Company completed its annual impairment testing for indefinite-lived intangible assets after the fourth quarter of 2011. Based on (i) assessment of current and expected future economic conditions, (ii) trends, strategies and projected revenues from sales of MYO-T12® and (iii) assumptions similar to those that market participants would make in valuing the Company's intangible assets, management determined that the carrying values of the intellectual property intangible assets exceeded its fair value. Accordingly, the Company recorded noncash impairment charges totaling \$2,662,000 for the year ended December 31, 2011, reducing the MYO-T12 intellectual property asset to its fair value of \$2,000,000.

NOTE 9 - INCOME TAXES

The Company has the following deferred tax assets and liabilities:

	<u>June 30, 2012</u>	<u>December 31, 2011</u>
Noncurrent assets and liabilities		
Intellectual property	\$ 1,000,000	\$ 1,038,000
Net operating loss carryforwards	1,285,000	843,000
	<u>2,285,000</u>	<u>1,881,000</u>
Valuation allowance	(2,285,000)	(1,881,000)
Net deferred tax asset	<u>\$ -</u>	<u>\$ -</u>

The valuation allowance for the deferred tax asset increased by \$404,000 for the six months ended June 30, 2012.

The Company has net operating losses amounting to approximately \$3,212,000 that expire in various periods through 2031. The ultimate realization of the net operating losses is dependent upon future taxable income, if any, of the Company and may be limited in any one period by alternative minimum tax rules. Although management believes that the Company will have sufficient future taxable income to absorb the net operating loss carryovers before the expiration of the carryover period, the current global economic crisis imposes additional profitability risks that are beyond the Company's control. Accordingly, management has determined that a full valuation allowance of the deferred tax asset is appropriate at this time.

Internal Revenue Code Section 382 imposes limitations on the use of net operating loss carryovers when the stock ownership of one or more 5% shareholders (shareholders owning 5% or more of the Company's outstanding capital stock) has increased by more than 50 percentage points. Management intends to carefully monitor share ownership of 5% shareholders but cannot control the ownership changes occurring as a result of public trading of the Company's Common Stock. Accordingly, there is a risk of an ownership change beyond the control of the Company that could trigger a limitation of the use of the loss carryover.

The Company has no uncertain income tax positions.

The tax years ended December 31, 2007 through 2011 are open for examination by federal and state taxing authorities. The Company has not filed all required federal and state income tax returns for years prior to 2010.

MYOS CORPORATION AND SUBSIDIARY
(a development stage company)
Notes to Consolidated Financial Statements
June 30, 2012 and 2011

The statutory federal income tax rate and the effective rate are reconciled as follows:

	June 30, 2012	December 31, 2011
Statutory federal income tax rate	34%	34%
State taxes, net of federal tax benefit	5%	5%
Valuation allowance	(39)%	(39)%
Net deferred tax asset	-%	-%

NOTE 10 - COMMITMENTS, CONTINGENCIES AND OTHER COMMENTS

Distribution Agreement

On May 16, 2012, the Company entered into a distribution agreement (the “Distribution Agreement”) with Maximum Human Performance, a company engaged in the development, marketing and distribution of nutritional and other therapies for consumer use (“MHP”). Pursuant to the Agreement, MHP will, on an exclusive basis, provide marketing, sales and distribution of MYO-T12, in retail and other outlets. MHP agreed to pay the Company \$195,301 upon the execution of the Distribution Agreement, with such amount to be credited against future purchase orders by MHP. The Distribution Agreement also provides additional supply and payment rights to MHP, on a non-exclusive basis, upon the termination of MHP’s exclusivity rights. The term of the Distribution Agreement is one year, with an effective date for exclusivity beginning on September 29, 2012. In the event MHP achieves certain sales targets for MYO-T12, the exclusivity provisions of the Distribution Agreement will be extended for an additional one or two years.

Employment Agreements

J.B. Bernstein: On February 25, 2011, the Company entered into an employment agreement with J.B. Bernstein, pursuant to which Mr. Bernstein served as Chief Executive Officer of the Company. The employment agreement was amended effective as of March 1, 2011. On April 30, 2012, J.B. Bernstein resigned from his positions as President and Chief Executive Officer and as a member of the Company’s board of directors. In connection with his resignation, Mr. Bernstein entered into a consulting agreement with the Company (the “Consulting Agreement”), pursuant to which Mr. Bernstein will be entitled to a consulting fee of \$5,000 per month during the six-month term of the Consulting Agreement. The Consulting Agreement also includes confidentiality and non-competition obligations and provisions for intellectual property assignments by Mr. Bernstein.

Carlton Colker MD, FACN: On February 25, 2011, concurrent with the closing of the Acquisition, the Company entered into an employment agreement with Carlton Colker, MD, FACN, pursuant to which Dr. Colker will serve as Chief Medical Officer and Executive Vice President of the Company. On June 14, 2012, Dr. Carlton Colker resigned from his positions as Chief Medical Officer and Executive Vice President. Simultaneously with his resignation, Dr. Colker agreed to serve on the Company’s Scientific Advisory Board. In connection with his appointment to the Scientific Advisory Board, Dr. Colker entered into an advisory board agreement with the Company, pursuant to which the Company issued him 300,000 shares of common stock. The Agreement also includes standard confidentiality and non-competition obligations and provisions for intellectual property assignments by Dr. Colker.

Peter A. Levy: On February 10, 2012, the Company entered into an employment agreement (the “Agreement”) with Peter Levy, age 51, pursuant to which Mr. Levy will serve as the Company’s Chief Operating Officer and Executive Vice President.

Pursuant to the terms of the Agreement, Mr. Levy will work for the Company on a full-time basis and will receive an annual base salary of \$200,000. Mr. Levy will be entitled to such bonus compensation (e.g. cash, stock or other property) as determined by the Company’s board of directors in its sole discretion. In addition, upon signing, Mr. Levy was granted 500,000 shares of the Company’s common stock, which shares will vest semi-annually commencing on August 10, 2012. The term of the Agreement is two years, and the Agreement will automatically renew for successive two-year periods, unless a notice of non-renewal is provided by either party more than 60 days prior to the expiration date of the term.

In the event Mr. Levy’s employment with the Company is terminated as a result of his death, his estate will be entitled to receive any accrued and unpaid compensation through the date of termination and certain benefits for six months following the date of termination. In addition, all of his unvested options will expire immediately and any vested options will expire twelve months following the date of termination. In the event Mr. Levy’s employment with the Company is terminated as a result of a disability, he will be entitled to receive his base salary for six months following the date of termination and certain benefits for twelve months following the date of termination. In addition, all of his unvested options will expire immediately and any vested options will expire twelve months following the date of termination.

MYOS CORPORATION AND SUBSIDIARY
(a development stage company)
Notes to Consolidated Financial Statements
June 30, 2012 and 2011

In the event Mr. Levy's employment with the Company is terminated for any reason other than death or disability, he will be entitled to receive any accrued and unpaid compensation through the date of termination. If he is terminated without cause (as defined in the Agreement) or resigns for good reason (as defined in the Agreement), all of his unvested options will vest immediately and any vested options will expire twelve months following the date of termination. If Mr. Levy is terminated for cause, all unvested options will expire immediately and any vested options will expire three months following the date of termination. In lieu of any severance payment, Mr. Levy is entitled to receive \$40,000 on the effective date of the Agreement.

Sponsorship Agreement

On June 27, 2011, the Company entered into a one year agreement with a celebrity spokesperson pursuant to which the spokesperson agreed to perform certain services for the Company and granted the Company the worldwide right to use the spokesperson's name and approved image in various media. The agreement provided for cash compensation of \$150,000 in three equal installments of \$50,000, all of which has been paid prior to June 30, 2012. Royalties at the rate of \$0.50 per unit sold are payable to the spokesperson for the term of the agreement and an additional 12 months thereafter. The agreement expired in June 2012.

The agreement also provided for the issuance of warrants to purchase 150,000 shares of common stock, 100,000 of which were issued upon signing of the agreement and 50,000 of which were issued in December 2011. The warrants have a term of two years with an exercise price of \$1.00 per share. The warrants further provide that in the event (a) the trading price of the common stock of the Company on its principal trading market does not exceed \$2.00 within two years of issuance and (b) the warrants were not exercised prior to such time, then the spokesperson shall have the right to sell any unexercised portion of the warrants to the Company in exchange for \$1.00 for each share of common stock underlying the unexercised portion of the warrants.

The 100,000 warrants issued upon execution of the agreement and the 50,000 warrants issued in December 2011 were valued at \$88,600 and \$48,050, respectively, using a Black-Scholes option pricing model and determining that the put option was the predominant feature of the instrument.

Director and Advisory Board Agreements:

Dr. Louis Aronne:

On July 14, 2011, the Company entered into two separate agreements with Dr. Louis Aronne to be a member of the Board of Directors and the Scientific Advisory Board.

The director agreement provides for compensation in the form of 100,000 shares of restricted common stock vesting in five equal annual installments commencing on execution of the agreement and an option to purchase 250,000 shares of common stock at an exercise price of \$0.64 for 10 years vesting over a period of 3 years, the first installment of which vested immediately. Upon a Change of Control, the unvested shares and the option will vest immediately. The advisory board agreement has a term of 5 years and provides for the issuance of 500,000 shares vesting in five equal annual installments commencing July 14, 2012 and an option to purchase 500,000 shares at \$0.64 per share vesting in four equal annual installments, and the first installment vested immediately upon the execution of the agreement. Upon a Change of Control, all unvested options shall immediately vest.

Dr. Robert Hariri:

On July 26, 2011, the Company entered into an agreement with Dr. Robert Hariri to be a member of the Board of Directors. The director agreement provides for 100,000 shares of restricted common stock vesting in five equal annual installments (the first installment of which vested immediately) and an option to purchase 250,000 shares of common stock at an exercise price of \$0.69 for 10 years vesting over a period of 3 years, the first installment of which vested immediately. Upon a Change of Control, the unvested shares and the option shall immediately vest.

MYOS CORPORATION AND SUBSIDIARY
(a development stage company)
Notes to Consolidated Financial Statements
June 30, 2012 and 2011

Dr. Peter Diamandis:

On August 15, 2011, the Company entered into an agreement with Dr. Peter Diamandis to be a member of the Board of Directors. The director agreement provides for 100,000 shares of restricted common stock vesting in five equal annual installments commencing (the first installment of which vested immediately) and an option to purchase 250,000 shares of common stock at an exercise price of \$0.45 for 10 years vesting over a period of 3 years, the first installment of which vested immediately. Upon a Change of Control, the unvested shares and the option shall immediately vest.

Dr. Buzz Aldrin: On May 24, 2012, the Company entered into an agreement with Dr. Buzz Aldrin to be a member of the Board of Directors. The director agreement provides for 100,000 shares of restricted common stock vesting in five equal annual installments commencing (the first installment of which vested immediately) and an option to purchase 250,000 shares of common stock at an exercise price of \$0.14 for 10 years vesting over a period of 3 years, the first installment of which vested immediately. Upon a Change of Control, the unvested shares and the option shall immediately vest.

Stock-Based Compensation:

We do not have a formal stock compensation plan. Although we do not have a formal plan, we do grant restricted common stock awards to consultants from time to time. Additionally, during the six months ended June 30, 2012 and the year ended December 31, 2011, we granted options to directors to acquire an aggregate of 250,000 and 1,250,000 shares of restricted common stock, respectively. 423,611 have vested and 1,076,389 remain unvested at June 30, 2012. The vesting terms range from 3 to 4 years and the options have a weighted average remaining term of 9.21 years and a weighted average exercise price of \$0.53 per share.

During the six months ended June 30, 2012, the Company issued an aggregate of 2,680,000 shares of restricted common stock to consultants and an officer for services. The 750,000 shares issued to an officer do not start to vest until August 2012. The shares issued were valued at trading prices on the date of issuance of between \$0.09 and \$0.45 per share for an aggregate charge of \$382,025.

NOTE 11 - SUBSEQUENT EVENT

Offering of Unregistered Securities

On July 6, 2012, the Company issued an aggregate of 19,980,000 shares of restricted common stock to accredited investors in a private placement and received aggregate gross proceeds of \$4,995,000. The securities are subject to registration rights.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Plan of Operation

We are focused on the development and commercialization of therapeutic and dietary products relating to muscle health, including the formulation, acquisition and distribution of nutritional, nutraceutical, physical performance enhancement and wellness products. Our initial core brand product is MYO-T12, a myostatin-inhibiting product. Our operations are supported by outside third party vendors, who also provide the order processing controls, such as electronic data interface with our customers. Our plan of action over the next twelve months is to produce our nutrition maximization and wellness products (principally our core product MYO-T12) for sale by our exclusive distributor, Maximum Human Performance ("MHP"), and to research and test new products in this area. The distribution agreement with MHP represents a significant shift away from our previous plan to market the product to the consumer as well as other retail distributors directly. Instead, we will co-brand our product under the MHP name and we will no longer be directly marketing or distributing the product. Our focus now will be to concentrate on reducing the cost of the product by finding more efficient manufacturing partners, conducting clinical trials of MYO-T12 and developing new products.

Three Months and Six Months Ended June 30, 2012 compared to the Three Months and Six Months Ended June 30, 2011

We are a development stage company that has generated minimal revenues. For the three months ended June 30, 2012, we generated revenues of \$343,889 and incurred a net loss of \$1,584,857. For the six months ended June 30, 2012, we generated revenues of \$368,429 and incurred a net loss of \$2,083,708. Revenues for both the three months and six months ended June 30, 2012 include sales to MHP of \$312,480. Related to the sale to MHP, we incurred a co-op advertising obligation of \$117,180 which was included in General and Administrative expenses for both periods. The net of the revenues and co-op advertising obligation was covered by the initial contract payment by MHP of \$195,301. In order to continue as a going concern and achieve a profitable level of operations, we will need, among other things, additional capital resources and to develop a consistent source of revenues. We believe the distribution agreement with MHP will enable us to achieve the expected sales growth and we currently have sufficient product inventory to adequately fulfill a reasonable influx of orders in response to increased advertising and marketing.

In the period from April 11, 2007 (inception) to June 30, 2012, we generated revenues of \$467,904 (including the sale to MHP of \$312,480) while incurring \$5,824,986 in general and administrative expenses. The cumulative net loss since inception was \$7,814,954, including net non-cash derivatives valuation adjustments of \$1,450,676 and intellectual property impairment charges of \$2,662,000. For the six months ended June 30, 2012, we incurred general and administrative expenses of \$1,033,007 compared to \$2,324,387 for the six months ended June 30, 2011. Upon completion of our annual impairment testing for indefinite-lived intangible assets after the fourth quarter of 2011, we determined that the carrying values of the intellectual property intangible assets exceeded its fair value and we recorded noncash impairment charges totaling \$2,662,000 in the Consolidated Statement of Operations, reducing the carrying value of the asset to its fair value of \$2,000,000. We are required to revalue certain derivative financial instruments each quarter and the change in value from the dates of their original issuance in 2011 resulted in an increase to our net loss for the six months ended June 30, 2012 by \$245,764. Such revaluations do not affect our cash flow.

Liquidity and Capital Resources

As of June 30, 2012, we had cash of \$571,840 and \$3,073,645 in total assets (which includes \$2,000,000 of intangible assets). For the six months ended June 30, 2012, we used cash of \$710,359 for operating activities. We received aggregate gross proceeds of \$1,745,000 from private placements of our securities during the quarter. The first installment of \$350,000 on the note payable to Peak was paid on November 29, 2011 and the second and final installment of \$350,000 was paid on February 21, 2012. In July 2012, the Company issued an aggregate of 19,980,000 shares of restricted common stock to accredited investors in a private placement and received aggregate gross proceeds of \$4,995,000. We believe that with those additional private placement proceeds received, we will have sufficient funds for operations, inventory procurement and product development for the next 12 months.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Critical Accounting Policies

Use of estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes, and disclosure of contingent liabilities at the date of the financial statements. Estimates are used for, but not limited to, the selection of the useful lives of property and equipment, provisions necessary for contingent liabilities, fair values, revenue recognition, taxes, budgeted costs and other similar charges. Management believes that the estimates utilized in preparing its financial statements are reasonable and prudent. Actual results could differ from these estimates.

Impact of Derivative Accounting

As a result of recent financing transactions we have entered into, our financial statements are impacted by the accounting effect of the application of derivative accounting. ASC Topic 815 and ASC Topic 815-40 govern the accounting treatment for both freestanding and embedded derivative financial instruments in our financial statements. Generally, warrants, conversion features in debt, and similar terms that include “full-ratchet” or reset provisions, which mean that the exercise or conversion price adjusts to pricing in subsequent sales or issuances, no longer meet the definition of indexed to a company's own stock and are not an exemption for equity classification provided in ASC Topic 815-15. The amount of non-cash gains or losses we record is based upon the fair market value of our common stock on the measurement date. The fair value of certain warrants outstanding which have “full-ratchet” or reset provisions (whereby the exercise or conversion price adjusts to pricing in subsequent sales or issuances in certain instances) is based on judgment as to expected future volatility of our common stock.

Long-lived assets

We apply the provisions of Financial Accounting Standard Board (“FASB”) Accounting Standards Codification (“ASC”) No. 360, “Property, Plant and Equipment”. ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable through the estimated undiscounted cash flows expected to result from the use and eventual disposition of the assets. Whenever any such impairment exists, an impairment loss will be recognized for the amount by which the carrying value exceeds the fair value.

The Company tests long-lived assets, including property, plant and equipment and other assets, for recoverability at least annually or more frequently upon the occurrence of an event or when circumstances indicate that the net carrying amount is greater than its fair value. Assets are grouped and evaluated at the lowest level for their identifiable cash flows that are largely independent of the cash flows of other groups of assets. The Company considers historical performance and future estimated results in its evaluation of potential impairment and then compares the carrying amount of the asset to the future estimated cash flows expected to result from the use of the asset. If the carrying amount of the asset exceeds estimated expected undiscounted future cash flows, the Company measures the amount of impairment by comparing the carrying amount of the asset to its fair value. The estimation of fair value is generally measured by discounting expected future cash flows as the rate the Company utilizes to evaluate potential investments. The Company estimates fair value based on the information available in making the necessary estimates, judgments and projections.

Fair Value of Indefinite-Lived Intangible Assets

The Company's policy is to evaluate indefinite-lived intangible assets for possible impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An intangible asset with an indefinite life (the intellectual property) is evaluated for possible impairment by comparing the fair value of the asset with its carrying value. Fair value is estimated as the discounted value of future revenues arising from a trademark using a royalty rate that an independent party would pay for use of that trademark. An impairment charge is recorded if the trademark's carrying value exceeds its estimated fair value. An impairment charge is recorded if the carrying value of the goodwill exceeds its implied fair value. See Note 8 for information related to impairment charges recorded in 2012 for indefinite-lived intellectual property intangible assets.

Equity Based Compensation

The Company accounts for equity-based compensation under the provisions of ASC 718-10 Compensation - Stock Compensation and ASC 505-50 Equity Based Payments to Non-Employees. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. For stock options and restricted stock that do not vest immediately but which contain only a service vesting feature, we recognize compensation cost on the unvested shares and options on a straight-line basis over the remaining vesting period, net of any projected forfeitures.

The Company uses the Black-Scholes option-pricing model as its method of valuation for share-based compensation. Our determination of fair value of share-based payment awards on the date of grant using an option-pricing model is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to our expected stock price volatility over the term of the awards, and certain other market variables such as the risk free interest rate.

Income taxes

The Company accounts for income taxes using an asset and liability approach which allows for the recognition and measurement of deferred tax assets based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will either expire before the Company is able to realize their benefits, or that future deductibility is uncertain.

The Company records a valuation allowance for deferred tax assets, if any, based on its estimates of its future taxable income as well as its tax planning strategies when it is more likely than not that a portion or all of its deferred tax assets will not be realized. If the Company is able to utilize more of its deferred tax assets than the net amount previously recorded when unanticipated events occur, an adjustment to deferred tax assets would increase the Company's net income when those events occur.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company and therefore are not required to provide the information for this item for Form 10-Q.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2012. Based on their evaluation, our principal executive officer and principal financial officer have concluded that, as of June 30, 2012, our disclosure controls and procedures were not effective.

Changes in Internal Controls.

There have not been any changes in the Company's internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June 30, 2012 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II- OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

None.

ITEM 1A. RISK FACTORS.

Factors that could cause our actual results to differ materially from those in this report are any of the risks described in our Annual Report for the year ended December 31, 2011 filed with the SEC. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations.

As of the date of this report, there have been no material changes to the risk factors disclosed in our Annual Report for the year ended December 31, 2011 filed with the SEC, except we may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

In April 2012, the Company issued an aggregate of 1,000,000 shares of restricted common stock to one accredited investor in a private placement and received aggregate gross proceeds of \$100,000.

In June 2012, the Company issued an aggregate of 2,400,000 shares of restricted common stock to certain accredited investors in a private placement and received aggregate gross proceeds of \$600,000.

The securities were issued pursuant to the exemptions from registration provided by Section 4(2) of the Securities Act and/or Regulation D promulgated thereunder since the foregoing issuances did not involve a public offering, the recipients took the securities for investment and not resale, the Company took appropriate measures to restrict transfer, and the recipients were "accredited investors". No underwriters or agents were involved in the foregoing issuances and the Company paid no underwriting discounts or commissions.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None

ITEM 4. MINE SAFETY DISCLOSURES.

None

ITEM 5. OTHER INFORMATION.

None

ITEM 6. EXHIBITS

Exhibit No.	Description of Exhibit
10.1**	Distribution Agreement between the Company and Maximum Human Performance dated May 16, 2012
31.1	Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act Of 2002
32.2	Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act Of 2002
101.INS *	XBRL Instance Document
101.CAL *	XBRL Taxonomy Extension Calculation Linkbase Document
101.SCH *	XBRL Taxonomy Extension Schema Document
101.DEF *	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB *	XBRL Taxonomy Extension Labels Linkbase Document
101.PRE *	XBRL Taxonomy Extension Presentation Linkbase Document

* XBRL (eXtensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

** Certain portions have been omitted pursuant to a confidential treatment request. Omitted information has been filed separately with the SEC.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 3, 2012

MYOS Corporation

By: /s/ Peter Levy

Name: Peter Levy

Title: Chief Operating Officer



CONFIDENTIAL TREATMENT REQUESTED
WITH RESPECT TO CERTAIN PORTIONS HEREOF
DENOTED WITH “*”**

DISTRIBUTION AGREEMENT

This Distribution Agreement (“Agreement”) is by and between Atlas Therapeutics, doing business as Myos Corporation, with its principal place of business at 45 Horsehill Road, Suite 106, Cedar Knolls, NJ 07927, hereinafter referred to as “MYOS”, and Maximum Human Performance, a Delaware Limited Liability Company, with its principal place of business at 21 Dwight Place, Fairfield, NJ 07004, hereinafter referred to as “MHP”, together referred to as the “Parties” and individually as a “Party”; and

WHEREAS, MYOS is in the business of developing nutritional and other therapies for consumer and medical use, and is the owner of the product and formulation for MYO-T12, a fecunded egg product for which MYOS has exclusive rights and that has been clinically shown to reduce myostatin levels; and

WHEREAS, MYOS owns the exclusive rights to the making of the formulation currently produced by a European food facility and the exclusive rights to the making of the formula should it be produced by any other entity; and

WHEREAS, MHP is a company engaged in the development, marketing and distribution of nutritional and other therapies for consumer and other use; and

WHEREAS, MYOS desires to have their product and formula marketed for sales to consumers and others, and MHP desires to market the MYO-T12 product name and formula for sales to consumers and others

NOW THEREFORE, the Parties agree to the following:

1. **INTENT** The Parties intend to enter into an exclusive distribution agreement for the product and formula currently known as MYO-T12 under a name to be determined by MHP at its sole discretion (the “Product”), and
2. **SCOPE** MHP, on an exclusive basis, will provide Marketing, Sales and Distribution of the Product in retail and on-line/internet outlets in the Sport Nutrition category, and in other outlets as the Parties may agree
3. **TERRITORY** The Territory for this Agreement shall be the United States and its territories. In addition, MHP shall have rights of first refusal for exclusive rights to any country that MYOS is interested in negotiating exclusive distribution of the Product. MHP shall have a non-exclusive right to sell the Product in all other countries and territories. In the event that MHP elects not to obtain exclusive rights in any country, or in the event that MHP and MYOS cannot agree on exclusive rights in any country, MYOS shall be free to enter into an exclusive distribution agreement for the Product with any third party. However, in the event that MHP is selling in such country on a non-exclusive basis, MYOS shall give MHP 120 days notice in order for MHP to wind-up their distribution of the Product in that country, and further, [***] of the product in the country contemplated. For sales in any country outside of the United States and its territories, MHP shall be responsible for ensuring that the Product meets any and all requirements in such country, and may, at its own cost, duly register the Product in such country. MYOS agrees to cooperate in providing information necessary for registering the Product as contemplated herein.

CONFIDENTIAL TREATMENT REQUESTED
WITH RESPECT TO CERTAIN PORTIONS HEREOF
DENOTED WITH “*”**

4. **TERM** This Agreement is for a term of one (1) year on an exclusive basis, with an effective date for exclusivity beginning 120 days from the first day of the month following the execution of this Agreement, with exclusivity extended for a second year or beyond subject to the terms and conditions described herein.
5. **SUPPLY** MYOS shall use reasonable commercial efforts to provide the product in a timely manner in accordance with any purchase orders from MHP, which shall provide for delivery dates for the Products not less than [***] from date of any purchase order.
6. **COST OF PRODUCT** Each unit of the Product, currently described as a 300 gram powder packaged in a manner to be prescribed by MHP, shall be at a net cost not to exceed \$[***] in a manner to be prescribed by MHP.

MYOS acknowledges it is customary for sports nutrition powder products to have a shelf life of [***], which is desired by MHP. In the event of a product issue that renders a product unfit for human consumption within [***] of manufacturing, MHP shall be entitled to a credit for any units affected. The Parties agree that they will cooperatively work together to establish testing procedures and parameters for the intended purpose of extending product shelf life to [***].

7. **CONTRIBUTION** MHP agrees to pay at the signing of this Agreement the sum of \$195,301.00, such sums to be credited against future purchase orders of Product by MHP to MYOS.

CONFIDENTIAL TREATMENT REQUESTED
WITH RESPECT TO CERTAIN PORTIONS HEREOF
DENOTED WITH “*”**

8. CO-OP MYOS agrees to provide cooperative marketing in the amount of \$[***] ordered by and shipped to MHP, such credit to be given by check within 15 days of the first of the month after any ordered and shipped Product is paid for by MHP, or provided as a credit against invoice to MHP, at the discretion of MYOS.

9. COG REDUCTION The Parties agree to work cooperatively to reduce the Cost of Goods (COG), including but not limited to bulk formula and packaging costs. The Parties agree that any such reduction in the COG shall be [***] as follows:

[***].

10. WARRANTIES AND REPRESENTATIONS MYOS warrants that MYO-T12 and/or bulk formula, including currently package Product and bulk formula, are in full regulatory compliance with the applicable regulatory bodies, and manufactured in accordance with Current Good Manufacturing Practices (cGMP). MYOS shall provide or cause to be provided all typical and requisite documentation regarding the ingredients, blending, manufacturing, packaging and shipping of the Product and importation of bulk formula from any supplier. Any delays in meeting quality standards or to deliver the Product in a timely manner shall extend the exclusivity period accordingly. MHP shall have the opportunity and right to inspect any and all facilities and review all testing and documentation prior to the effective date.

MHP shall be responsible and liable determining the appropriate product shelf life dating, and MYOS shall be responsible for ensuring the Product is tested for the purposes of establishing extended shelf life dating, and shall provide any and all such tests and data to MHP to assist in their determination of shelf life dating.

MHP shall be responsible for and shall pay for all marketing, distribution, storage, shipping, and other ordinary costs incurred in marketing products similar to the Product. MHP shall use its best commercial efforts to promote the Product, and MYOS agrees to provide reasonable and customary support for MHP's efforts in promoting the product. MHP shall develop a marketing plan for the Product as is typical for such Product. MYOS shall have the right to periodically review the sales, marketing and promotional efforts of MHP for the Product, such review not more frequently than four (4) times in any 12 month period.

11. RIGHT TO INSPECT AND APPROVE MHP shall have the right to inspect and improve any facility involved in the blending, packaging or other manufacturing operations involved in making the product for the purposes of maintaining MHP's cGMP compliance and to ensure that all aspects of the product are made according to the applicable rules and regulations for the product.

CONFIDENTIAL TREATMENT REQUESTED
WITH RESPECT TO CERTAIN PORTIONS HEREOF
DENOTED WITH “*”**

12. CEASE OF OPERATIONS; INSOLVENCY In the event that MYOS ceases operations for any reason, or in the event MYOS becomes insolvent, files for bankruptcy protection or becomes unable to financially meet the requirements of this Agreement, MHP shall have the right to work directly with any entity involved in making or managing the product, and MYOS shall assign any and all rights and/or agreements it has with any such entity to MHP in order for MHP to continue the business as contemplated herein. In the event of any such cease of operations or insolvency or bankruptcy as contemplated herein, [***] to MYOS or any entity or party so designated and approved by the Board of Directors of MYOS, or as designated by any bankruptcy trustee or court of competent jurisdiction, as its sole obligation to obtain all rights owned by MYOS and for all rights related to the Product hereunder under the control of MYOS for all stated purposes of this Agreement.
13. CO-BRANDING The Product as packaged in the manner prescribed by MHP shall conspicuously depict the name MYO-T12 on its principal display panel, and MYOS will have the right to approve such depiction, said approval not to be unreasonably withheld.
14. TRADEMARK MHP shall have the right to exclusively use the mark MYO-T12 owned by MYOS for all purposes contemplated hereunder for such period of time that MHP has exclusive rights to the Product. Upon expiration of the exclusive rights of MHP to the Product, MHP shall have a non-exclusive right to use the mark MYO-T12 for as long as they are marketing and distributing the Product. MHP shall state clearly that the MYO-T12 mark is a registered trademark of MYOS Corp on each unit of product, and in advertising and promotion, whenever the MYO-T12 mark is used.
15. EXTENSION OF EXCLUSIVITY It is understood that exclusivity is being granted based on MHP’s good faith, industry knowledge and experience that MHP can achieve sales of \$[***] of the Product in retail establishments during the exclusivity period. If MHP achieves such sales of at least \$[***] dollars, the exclusivity period shall be extended for an additional one year period. In year two, if MHP increases its sales of the Product greater than [***]% over year one, MHP shall be granted exclusivity for an additional one year period. The Parties further agree to consider, in good faith, negotiating additional extensions of the exclusivity for successive one year periods beyond what is contemplated herein at least 90 days prior to expiration of any exclusivity period. In the event that the exclusivity provisions are not extended after year two, as contemplated herein, MYOS agrees to [***] to other entities that MYOS may sell to after MHP’s exclusivity is terminated for a period of [***] in recognition of MHP’s pioneering efforts in developing the category. In the event that the exclusivity provisions are not extended after year three, as contemplated herein, MYOS agrees to [***] to other entities that MYOS may sell to after MHP’s exclusivity is terminated for a period of one (1) year in recognition of MHP’s pioneering efforts in developing the category.

CONFIDENTIAL TREATMENT REQUESTED
WITH RESPECT TO CERTAIN PORTIONS HEREOF
DENOTED WITH “*”**

16. [***].

17. **NEW ITEMS** The Parties to agree to use their best efforts to work collaboratively on developing new items that will achieve the goals of introducing new items that meet the financial goals of the Parties, including lowering COG and structuring a profit model that is mutually beneficial and agreeable. The Parties agree that after the effective date of this Agreement that they will separately negotiate and agree to a development and pricing model on new items.

18. **INSURANCE** Both Parties shall maintain liability insurance in amounts necessary to protect the interests of each Party, as stated below. Each Party shall name the other Party as an additional insured. Each party shall provide a copy of the declaration page evidencing such insurance and shall do so upon each renewal of any policy, and each shall provide the other at least thirty (30) days notice of any change or cancellation of any policy.

Commercial General Liability	
General Aggregate Limit	\$10,000,000
Products/Completed Operations	\$5,000,000
Each Occurrence	\$5,000,000
Advertising Injury and Personal Injury Aggregate Limit	\$10,000,000

19. **INDEMNIFICATION** The Parties agree to indemnify, defend, and hold each other harmless as well as its parents, subsidiaries, affiliated companies, and their respective current and former directors, officers, employees, contractors, stockholders, agents and representatives (collectively, the “Indemnified Parties”), from and against any and all Claims for their respective willful or grossly negligent actions or inactions under this Agreement. The Indemnified Parties shall give the other prompt written notice of any Claim(s), although failure to do so shall not excuse a Party's obligations hereunder except to the extent that material prejudice directly results from such a failure. The Indemnified Parties shall provide reasonable assistance to the other in defending the Claim and/or may, at its option, participate in the settlement or defense of any such Claim with its own counsel and at its own expense.

CONFIDENTIAL TREATMENT REQUESTED
WITH RESPECT TO CERTAIN PORTIONS HEREOF
DENOTED WITH “*”**

20. NOTICES Any notice or other communication given pursuant to this Agreement shall be in writing and shall be deemed duly given (a) when delivered personally to the party for whom intended, (b) five (5) days following deposit of the same into the United States mail (certified mail, return receipt requested, or first class postage prepaid), (c) when sent by facsimile (with confirmation of delivery), (d) by electronic mail so long as receipt by the other party is acknowledged by the other party or by return receipt, or (e) on the designated day of delivery after being timely given to an overnight delivery service (with confirmation of delivery). Notice shall be deemed given when delivered to the respective addresses set out above, or to such other address as a Party shall specify.

21. ASSIGNMENT This Agreement shall not be assignable by either party without the express written consent of the non-assigning party, such consent not unreasonably withheld. Notwithstanding the foregoing, this Agreement shall be assignable by either Party in the event of a change in the controlling interest in a Party, such controlling interest defined as sale of more than 50% of the stock or assets of a Party. In the event of such a change, the Party wishing to assign this Agreement shall provide the non-assigning party prompt notice of its intent to assign.

22. AUTHORITY Each Party who affixes their signature below warrants and agrees to defend that they have the power and is duly authority to enter into and bind their respective organizations to all matters and obligations herein.

23. COOPERATION Each Party agrees to provide their full cooperation in defending against any and all 3rd parties who attempt to interfere with or unfairly compete with the intellectual property, formula, business or trade secrets relating to the Product. Each Party agrees that upon receiving any information of any potential infringement or interference that they shall promptly notify the other Party of such potential infringement or interference.

24. MISCELLANEOUS

(a) INDEPENDENT PARTIES The relationship between the Parties is that of independent organizations and neither party will be considered, or hold itself out as, an agent, partner, joint venture, or representative of the other for any purpose. Nothing in this Agreement shall be construed to establish a relationship that would allow either party to make representations, warranties or commitments on behalf of the other party.

CONFIDENTIAL TREATMENT REQUESTED
WITH RESPECT TO CERTAIN PORTIONS HEREOF
DENOTED WITH “*”**

(b) **CONFIDENTIAL INFORMATION** Each party (the “Disclosing Party”) agrees not to disclose any Confidential Information to the other party (the “Receiving Party”), except to its own employees and agents who have a legitimate reason to know such information and who are obligated to treat such information as confidential, and not to use or exercise its rights under the Agreement. “Confidential Information” means any information, technical data, product information, personal and customer information, financial information, business plans, unpublished financial reports, R&D plans, marketing information, employee or consultant information, technology, suppliers, methodology or know-how of the Disclosing Party that is disclosed by the Disclosing Party to the Receiving Party or that is otherwise learned by the Receiving Party in the course of its business dealings with the Disclosing Party, and that has been identified as being proprietary and/or confidential or that by the nature of the circumstances surrounding the disclosure or receipt ought to be treated as proprietary and/or confidential. Confidential Information does not include information that (i) is or becomes publically available through no fault of Receiving Party; (ii) can be shown by documentation to have been known by the Receiving Party prior to its receipt from the Disclosing Party; (iii) is rightfully received from a third party who did not acquire or disclose such information by a wrongful or tortious act; or (iv) can be shown by documentation to have been developed by the Receiving Party without reference to any Confidential Information. If the receiving party becomes legally obligated to disclose Confidential Information to any governmental entity, the receiving party will give the disclosing party prompt written notice sufficient to allow the disclosing party to seek a protective order or other appropriate remedy. The receiving party will disclose only such information as is required by the governmental entity and will use its reasonable best efforts to obtain confidential treatment for any Confidential Information that is so disclosed. All Confidential Information will remain the exclusive property of the disclosing party, and the receiving party will have no rights, by license or otherwise, to use the Confidential Information except as expressly provided herein.

(c) **SUCCESSORS: ASSIGNMENT** This Agreement will be binding on and inure to the benefit of the parties and their respective successors in interest and assigns.

(d) **GOVERNING LAW; VENUE** This Agreement and the rights and obligations of the parties will be governed by and construed according to the laws of the state of New Jersey, without regard to its choice of law provisions. Any controversy arising under, in connection with or in any way relating to this Agreement shall be adjudicated before a state or federal court of competent jurisdiction located in Essex County, New Jersey. By the execution and delivery of this Agreement, each party (i) accepts, generally and unconditionally, the exclusive jurisdiction of such court and any related appellate court, and irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement, and (ii) irrevocably waives any objection it may now or hereafter have as to the venue of any such suit, action or proceeding brought in such a court or any argument based upon *forum non conveniens*.

CONFIDENTIAL TREATMENT REQUESTED
WITH RESPECT TO CERTAIN PORTIONS HEREOF
DENOTED WITH “*”**

(e) SEVERABILITY The provisions of this Agreement are severable, and in the event that any provision thereof is determined to be invalid or unenforceable, such invalidity or unenforceability will not in any way affect the validity or enforceability of the remaining provisions.

(f) AMENDMENT AND WAIVER Except as expressly specified herein, no amendment, waiver, or discharge of any provision of this Agreement will be effective unless made in writing, signed by both Parties.

(h) ENTIRE AGREEMENT This Agreement constitutes the entire agreement between the Parties with respect to the subject matter thereof and supersedes all prior agreements. This Agreement governs all transactions related to the subject matter of this Agreement and will supersede, reject, and displace any prior terms and conditions.

(i) COUNTERPARTS; FAX This Agreement may be executed in counterparts, each of which will be deemed an original, but both of which together will constitute one and the same instrument. In addition to any other lawful means of execution or delivery, this Agreement may be executed by (a) exchanging portable document format (PDF) images by email; or (b) facsimile signatures.

(rest of page left intentionally blank)

CONFIDENTIAL TREATMENT REQUESTED
WITH RESPECT TO CERTAIN PORTIONS HEREOF
DENOTED WITH “*”**

Signature Page

Made effective as of May 16, 2012.

Maximum Human Performance, LLC

Atlas Therapeutics

By: /s/ Gerard Dente _____

By: /s/ Peter Levy _____

Name: Gerard Dente

Name: Peter Levy

Title: CEO

Title: Chief Operating Officer

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A)
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Peter Levy, certify that:

1. I have reviewed this quarterly report on Form 10-Q of MYOS Corporation (the "report");
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: August 3, 2012

By: /s/ Peter Levy
Name: Peter Levy
Title: Chief Operating Officer

(Principal Executive Officer)

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A)
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Stewart W. Robinson, certify that:

1. I have reviewed this quarterly report on Form 10-Q of MYOS Corporation (the "report");
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: August 3, 2012

By: /s/ Stewart W. Robinson
Name: Stewart W. Robinson
Title: Interim Chief Financial Officer

(Principal Financial Officer)

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with this quarterly report on Form 10-Q of MYOS Corporation (the "Company") for the quarter ended June 30, 2012 (the "Report"), I, Peter Levy, the Principal Executive Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 3, 2012

By: /s/ Peter Levy
Name: Peter Levy
Title: Chief Operating Officer
(Principal Executive Officer)

This certification accompanies this report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the

extent required by such Act, be deemed filed by the Company for purpose of Section 18 of the Securities Exchange Act of 1934, as amended.

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with this quarterly report on Form 10-Q of MYOS Corporation (the "Company") for the quarter ended June 30, 2012 (the "Report"), I, Stewart W. Robinson, the Principal Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 3, 2012

By: /s/ Stewart W. Robinson
Name: Stewart W. Robinson
Title: Interim Chief Financial Officer
(Principal Financial Officer)

This certification accompanies this report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the

extent required by such Act, be deemed filed by the Company for purpose of Section 18 of the Securities Exchange Act of 1934, as amended.